Open AccessMultiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID‐19
Author(s) -
Cismaru Cosmin Andrei,
Cismaru Gabriel Laurentiu,
Nabavi Seyed Fazel,
Ghanei Mostafa,
Burz Claudia Cristina,
Nabavi Seyed Mohammad,
Berindan Neagoe Ioana
Publication year - 2021
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15927
Subject(s) - covid-19 , acute respiratory distress , respiratory distress , medicine , intensive care medicine , respiratory system , coronavirus infections , betacoronavirus , bioinformatics , anesthesia , virology , lung , biology , disease , infectious disease (medical specialty) , outbreak
Abstract COVID‐19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral‐induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID‐19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS‐CoV‐2 infection.